Viking Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research and development | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M |
| Operating expenses | $393.3M | $150.9M | $100.8M | $70.4M | $55.7M |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M |
| Pretax income | -$359.6M | -$110.0M | -$85.9M | — | — |
| Income tax expense | $1,000 | $1,000 | $1,000 | $1,000 | $2,000 |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M |
| Balance Sheet | |||||
| Cash and equivalents | $165.8M | $26.7M | $55.5M | $36.6M | $26.4M |
| Current assets | $715.6M | $907.2M | $367.2M | $167.0M | $210.5M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M |
| Current liabilities | $76.7M | $27.4M | $19.1M | $21.9M | $8.8M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M |
| Stockholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M |
| Stock-based compensation | $40.8M | $29.7M | $16.8M | $8.7M | $6.1M |
| Share repurchases | — | — | — | $6.8M | — |
Shares outstanding 116.1M · Free float 90.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.